Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.
Revolutionizing cancer therapy on a global basis by developing TCR therapies with the potential to treat a wide range of cancer types and patients.
Aduro’s three proprietary technology platforms (Live, Attenuated Double-Deleted Listeria (LADD), STING Pathway Activators, and B-select monoclonal antibodies) have the potential to transform the ...
Advaxis’ Lm Technology uses live, attenuated bioengineered Listeria monocytogenes (Lm) bacteria to stimulate the immune system to view tumor cells as potentially ...
Agenus uses the power of the immune system to develop innovative product candidates against cancer. The company has assembled a broad portfolio of antibodies including checkpoint inhibitors and ...
Aileron is developing stapled peptide therapeutics for cancers and other diseases. A stapled peptide is chemically stabilized to improved performance and activity for a broad range of alpha- ...
The company creates protein-based immunotherapies to treat cancer, autoimmune disorders, and other diseases.
Biologics. Amgen makes several therapeutic drugs that target serious disease. Many are derived from engineered monoclonal antibodies. Some target immune receptors.
Aminex Therapeutics, Inc., is a drug development company focused on discovery and development of a unique cancer drug therapy in the general category of cancer immunotherapies known as checkpoint ...
Uses modified antibodies to generate immunotherapeutics.
Developing novel cancer therapeutics designed to spare healthy cells while targeting tumor adaptive responses and cancer evasion pathways.
Developing PRDM Gene and Protein Modulation Agents as Anti-Cancer Products
Artios develops cancer treatments that target DNA Damage Response (DDR) pathways in order to selectively kill cancer cells.
Atara Bio’s programs include T-cell product candidates and molecularly-targeted product candidates.
Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. ...
Avalon GloboCare Corp. is a healthcare management provider and biotechnology developer, dedicated to integrating and managing global healthcare resources, empowering high-impact biomedical ...
Avergen is developing a drug discovery platform for identifying highly potent drugs for cancer treatment.
Stem Cell Technologies, Fully Human Biologics Manufacturing Cell Lines, Regenerative Medicine, CAR-T Immunotherapy & Cancer Treatment.
A biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Develops next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), CAR T cell therapy, and TCR ...
Besins Healthcare produces anti-cancer drugs, and hormone therapies.
Bicycles are a new therapeutic modality combining the attributes of antibodies, small molecules and peptides within one molecule. Bicycles exhibit the affinity and selective ...
bioAffinity Technologies, Inc. develops tests and therapies to detect and treat cancer at the cellular level with porphyrin molecules.
Biolyse Pharma specializes in manufacturing and developing of sterile oncology drugs.
- Currently produces Paclitaxel for the treatment of cancer, known for its mild side effects when ...
Real-time cancer cell visualization for surgical applications. Blaze is working to develop Tumor Paint products and Optide*-based guided therapeutics.
The cancer immunotherapy research group is focused on the next generation of T cell engineering and creating a pipeline of T cell product candidates (CAR T cells) to treat a wide variety of liquid ...
A biopharmaceutical company. They discover, develop, and deliver medicines to treat serious disease.
Develops novel compounds for cancer treatment. The most advanced product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor.
CellAct Pharma GmbH was founded by Fritz Kopitzki and Nalân Utku in 2007 as a venture backed biotech company. CellAct is focused on the development of innovative therapeutics for the treatment of ...
Small Molecules, Biologics, Vaccines, The pipeline is comprised of antibody-based therapies and other protein-based therapeutics that modulate the immune system or directly target tumors.
Designing next generation immunotherapies based on gene-edited CAR T-cells
Develops technology to activate the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells.
A private, non-profit, regional health care system.
CisThera’s mission is to develop innovative therapeutics to treat cancer, autoimmune diseases, as well as chronic kidney and liver diseases.
Develops molecules to activate Toll like receptors. These can be used to stimulate the innate immune system.
Codiak plans to define and engineer exosomes with single or multiple payloads directed against specific intracellular targets.
Compliment Corporation is a start-up biotechnology company developing revolutionary therapeutics in oncology. Our mission is to improve cancer treatment by dramatically increasing the ...
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers
Cullinan Oncology develops high value therapeutics geared towards dramatically improving the standard of care for those living with cancer.
Develops anti-cancer drugs.
CytImmune’s nanotherapy platform, Aurimune, is a tumor-targeted Trojan horse. Aurimune selectively binds TNF receptors on blood vessel cells at the site of disease. Once bound, Aurimune unleashes ...
Develops cancer immunotherapies, drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies based on Protease-Activated Antibodies, 'Probodies'
Immunotherapy treatment for prostate cancer.
Focused on therapies for cancer and inflammatory diseases
Activating the immune system to eradicate cancer. Focuses on regulatory T cells.
Committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Research and development programs currently focus on potential treatments in HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions ...
Develops anti-cancer immunotherapies